uploads/2018/09/Part2_graph.png

T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics

By

Updated

Autolus Therapeutics’ target price

Headquartered in London, Autolus Therapeutics (AUTL) is focused on developing next-generation T-cell therapies targeting multiple solid tumor and hematological indications. According to Autolus Therapeutics’ September investor presentation, the company expects to report proof-of-concept data from five programs in 2019.

Autolus Therapeutics has reported year-to-date returns of 9.0%. Autolus Therapeutics closed at $27.25 on September 25, which was 42.12% higher than the company’s 52-week low of $19.17 and 18.66% lower than the company’s 52-week high of $33.50.

The 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.” The 12-month consensus target price for the company is $35.00, which is 28.44% higher than its closing price on September 25. The highest target price estimate for the company is $38.00, and the lowest target price estimate is $30.00.

Of the four analysts covering Autolus Therapeutics in September, three analysts recommended the company as a “strong buy,” and one analyst recommended the company as a “hold.” The chart above highlights Autolus Therapeutics’ broad pipeline.

Revenue and EPS projections

Wall Street analysts expect Autolus Therapeutics (AUTL) to report revenues of $0.50 million in fiscal 2018, $0.50 million in fiscal 2019, and $0.67 million in fiscal 2020. Autolus Therapeutics is expected to report EPS of -$2.91 in fiscal 2018, -$2.43 in fiscal 2019, and -$2.06 in fiscal 2020.

According to Autolus Therapeutics’ recent investor presentation, the company had cash and cash equivalents of $250.0 million on its balance sheet on June 30. The company expects this cash level to sustain its operations until 2021.

In the next article, we’ll discuss the growth prospects for Rocket Pharmaceuticals.

More From Market Realist